Ligament-Derived Stem Cells: Identification, Characterisation, and Therapeutic Application by Lee, Katie Joanna et al.
Review Article
Ligament-Derived Stem Cells: Identification, Characterisation,
and Therapeutic Application
Katie Joanna Lee,1 Peter David Clegg,1,2,3 Eithne Josephine Comerford,1,2
and Elizabeth Gail Canty-Laird1,3
1Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool,
William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK
2School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston CH64 7TE, UK
3The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Liverpool, UK
Correspondence should be addressed to Katie Joanna Lee; leekj@liverpool.ac.uk
Received 30 December 2016; Accepted 19 February 2017; Published 12 March 2017
Academic Editor: Nicola Baldini
Copyright © 2017 Katie Joanna Lee et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Ligament is prone to injury and degeneration and has poor healing potential and, with currently ineffective treatment strategies,
stem cell therapies may provide an exciting new treatment option. Ligament-derived stem cell (LDSC) populations have been
isolated from a number of different ligament types with the majority of studies focussing on periodontal ligament. To date, only a
few studies have investigated LDSCpopulations in other types of ligament, for example, intra-articular ligaments; however, this now
appears to be a developing field. This literature review aims to summarise the current information on nondental LDSCs including
in vitro characteristics of LDSCs and their therapeutic potential.The stem cell niche has been shown to be vital for stem cell survival
and function in a number of different physiological systems; therefore, the LDSC niche may have an impact on LDSC phenotype.
The role of the LDSC niche on LDSC viability and function will be discussed as well as the therapeutic potential of LDSC niche
modulation.
1. Introduction
Ligament is prone to injury and degeneration, particularly
the anterior cruciate ligament (ACL) [1], with an incidence
of approximately 37 ACL ruptures per 100,000 people [2] and
a greater incidence among athletes [3]. Healing after ligament
injury is poor leaving abnormal scar tissue which frequently
is unable to function effectively [4]. The current treatment
strategies for ligament injury are limited with variable success
rates. Rest and physiotherapy are often prescribed along with
a knee brace for ACL injuries to aid stability of the knee [5].
In more severe cases or where conservative therapies have
failed, surgery is often performed; however, there appears
to be little difference in success outcomes between surgical
and conservative treatment options [6]. Most cases requiring
surgery for ACL ruptures undergo reconstruction of the
ligament using a section of the patients’ hamstring, or
patellar tendon, or, less commonly, allogeneic grafts. There
are variable success rates associatedwithACL reconstruction,
dependent upon the patient’s lifestyle, age, and health [6, 7];
however, recent advances in the field of stem cell research
may provide a treatment option with improved success rates.
For example, the injection ofmesenchymal stem cells (MSCs)
alone [8] or with the use of a biosynthetic scaffold [9] to
treat ACL rupture shows promising results at the preclinical
research stage. It is clear that stem cell therapies such as
MSCs hold potential for treatment of ligament injuries and
the identification of stem cells in ligament tissue [10]may also
provide a possible therapeutic option.
In 2004, Seo et al. identified a population of cells within
periodontal ligament which demonstrated certainMSC char-
acteristics, including clonogenicity, expression of stem cell
markers, and the ability to differentiate down a number of
different cell lineages [10]. Since then a large amount of
research has been conducted into periodontal ligament stem
cells (PDLSCs), both into the characterisation of these cells
[10, 11] and into their use in tissue engineering strategies
[12, 13].Therefore, themajority of published research on stem
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Figure 1: Differentmorphologies and clonogenic ability of LDSCs isolated from canine cranial cruciate ligament. (a)-(b) show sparse colonies
with a fibroblastic cell morphology. (c)-(d) show dense colonies with a rounded, cobblestone cell morphology. Bars = 100 𝜇m.
cells in ligament has focussed on PDLSCs. The promising
results seen with these cells may also be applicable for
other ligaments in other areas of the body, and in recent
years research has turned to the ACL and the potential for
ligament-derived stem cells (LDSCs) to provide therapies
for other types of ligament injury. This literature review will
focus on the identification, characterisation, and therapeutic
potential of LDSCs derived from nondental origins, with
particular emphasis on stem cells isolated from the ACL.
2. Isolation and Culture of LDSCs
The majority of studies investigating nondental LDSCs have
isolated cells from human ACLs (ACLDSCs) [14, 15]. How-
ever, there are a number of other studies which have isolated
and cultured LDSCs from other species, including horses
[16], pigs [17], and rabbits [18], as well as other ligament types,
including rabbit medial collateral ligament (MCL) [18] and
human interspinous ligament [19].
The isolation of LDSCs involves tissue extraction, diges-
tion in collagenase, and seeding of cells [14, 20] or, alterna-
tively, tissue extraction and outgrowth of cells from ligament
explants [21, 22]. Despite the different approaches to LDSC
isolation, cells obtained through tissue digestion or tissue
explants seem to demonstrate similar stem cell characteristics
[22]. Cells are then cultured in vitro and can be extensively
expanded up to 25 population doublings [21] or 20 passages
[16]. Unlike other stem cell types, there is little research
on the optimum culture conditions for LDSC survival and
expansion. The survival and function of cells are normally
dependent upon the culture conditions, and oxygen tension
appears to have an effect on LDSC metabolism and matrix
production [23]. In addition, certain media formulations and
growth factors, such as basic fibroblast growth factor (bFGF)
and transforming growth factor 𝛽1 (TGF-𝛽1), promote stem
cell proliferation and differentiation [24].However, the effects
ofmany other factors associatedwith in vitro culturing of cells
have yet to be investigated.
3. Characteristics of LDSCs
3.1. Clonogenic Potential and Cell Morphology of LDSCs.
After several days in culture, the LDSCs start to form
heterogeneous colonies [20, 21], reflecting the heterogeneity
of cell populations and differences in proliferation rates [21].
The majority of studies have reported a fibroblastic cell
morphology of LDSCs [24, 25]; however, there seems to
be variation between ligament types. LDSCs isolated from
ACL and posterior cruciate ligament (PCL) demonstrated
a fibroblastic morphology [15, 21] and those from MCL a
polygonal morphology [18, 20]. LDSCs isolated from equine
suspensory ligaments (SLs) demonstrated a heterogeneous
morphology, with predominantly fibroblastic cells, but also
with the presence of smaller rounded cells [16]. We have
observed both rounded and fibroblastic cell morphologies
upon initial seeding of stem cells derived from canine cranial
cruciate ligament (CCL); however, the rounded morphology
was lost with passaging (Figure 1).
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Figure 2: Trilineage differentiation potential of canine cranial cruciate LDSCs. Images are shown for LDSCs after induction of osteogenic, adi-
pogenic, and chondrogenic differentiation after appropriate staining (a)–(e). Cells subjected to osteogenic differentiation media were stained
for both calcium deposits using alizarin red stain (a) and alkaline phosphatase activity (b). Cells subjected to adipogenic differentiationmedia
were stained for oil droplet formation using oil red O (c), and cell pellets exposed to chondrogenic differentiation media, for GAG formation
using alcian blue (d) and safranin O (e). Negative control cells were incubated in control media and stained as above (f)–(j). Bars = 100𝜇m.
3.2. Stem Cell and Tenogenic Marker Expression of LDSCs.
Many of the markers used to identify LDSCs are found in
other cell types, including MSCs and tendon-derived stem
cells (TDSCs) (Table 1).
Stem cells derived from human ACL tissue have been
shown to express the MSC markers CD13, CD29, CD44,
CD49c, CD73, CD90, CD97, CD105, CD146, CD166, SSEA-4,
STRO-1, andHLAA, B, C, aswell as the pluripotencymarkers
Oct4, Nanog, and Sox2, and demonstrate negative expression
ofCD34 andCD45 [20–22, 25]. Stem cells derived from rabbit
MCL have been shown to express CD44 and CD90 but not
CD34, CD106, or CD11b [18].
LDSCs have also been shown to express ligamentogenic
markers, indicative of their lineage. These markers include
the ligament extracellular matrix (ECM) proteins tenascin C
[14, 25] and tenomodulin [22].
3.3. Multipotency of LDSCs. As a subpopulation of MSCs,
LDSCs should be multipotent and have the potential to
differentiate into various cell types, including osteogenic,
adipogenic, and chondrogenic lineages.
LDSCs isolated from human ACL have been shown to
differentiate into osteogenic, adipogenic, and chondrogenic
cells. Osteogenesis was confirmed using alizarin red staining
for the identification of calcium nodule formation [25, 26]
and staining for alkaline phosphatase activity [15, 21]. In
addition, the expression of osteogenic marker genes such
as osteopontin, osteocalcin, collagen type I, Runx2, and
alkaline phosphatase was verified [15, 21]. Adipogenesis was
demonstrated using oil red O staining for lipid droplet
formation [25, 26], as well as analysis of adipogenic marker
gene expression, including FABP4, PPAR𝛾, and LPL [20,
21]. Chondrogenesis was confirmed using alcian blue and
toluidine blue staining for glycosaminoglycan formation [25,
26], as well as expression of chondrogenic marker genes
including collagen type II, SOX9, and aggrecan [15, 21].
Osteogenic, adipogenic, and chondrogenic differentia-
tion has also been demonstrated in other ligament types,
including LDSCs isolated from equine suspensory [16],
human interspinous [19], human medial collateral [20], and
human posterior cruciate [21] ligaments, as well as LDSCs
derived from canine CCL in our hands (Figure 2).
3.4. Variation between LDSCs Isolated from Different Liga-
ments. There are clear variations in stem cell characteristics
of cells isolated from different ligament types; however,
there are also some ligaments which share the same cellular
properties. LDSCs isolated from human ACL and PCL
share the same phenotype, with no discernible or significant
differences between the two cell populations [21]. In contrast,
there are a number of differences between LDSCs isolated
from ACL and MCL, with MCL derived cells demonstrating
increased clonogenicity and proliferation rates, increased
expression of stem cell marker genes, reduced osteogenesis,
and increased chondrogenesis compared with ACL derived
cells. In addition, cells isolated from the two ligaments
demonstrated differing morphologies with LDSCs fromACL
showing a fibroblastic morphology and cells from MCL a
polygonal morphology [20]. The possible reasons for these
differences have been attributed to the increased vascularity
of MCL when compared with ACL, with the subsequent
increased healing potential of MCL over ACL [27, 28] poten-
tially being a result of the differences in resident stem cell
populations [20]. Another study comparing the differences in
stem cell properties between cells isolated from rabbit ACL
and MCL found increased chondrogenesis of ACL derived
cells comparedwithMCL derived cells [29], which is in direct
contrast to the study discussed above [20]. This discrepancy
may be due to ligament cells being seeded at a higher density
in the latter study in order to avoid colony formation and
therefore their cell population was likely a mixed population
of cells with differing properties or, alternatively, species
variation may account for the differences [29].
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LDSCs are hypothesised to be a subset of MSCs and
these two cell populations share many stem cell character-
istics, however there are also important differences. LDSCs
from human ACL have been directly compared with bone
marrow-derived MSCs. LDSCs and MSCs both demonstrate
a fibroblastic morphology as well as the ability to form
colonies with LDSCs demonstrating increased clonogenicity
compared with MSCs; however, proliferation rates seem to
vary between studies [14, 22, 25]. Both cell types are able to
differentiate into osteogenic, adipogenic, and chondrogenic
cell types; however, osteogenic and chondrogenic potential
is increased in MSCs compared with LDSCs. In addition,
tendon/ligament marker expression is increased in LDSCs
compared with MSCs, although stem cell marker expression
seems to be consistent across cell types [14, 22, 25].
3.5. The Effects of Ageing and Injury on LDSCs. Ageing and
injury/degeneration have both been shown to have an effect
on the function and phenotype of various stem cell types,
includingMSCs [30, 31], TDSCs [32–34], and LDSCs isolated
from periodontal ligament [35, 36]. However, little is known
about the effects of these factors on LDSCs isolated fromACL
or other ligament types.
In LDSCs derived from human ACL, age has been shown
to cause a decrease in the rate of proliferation as well as
reduced osteogenesis [37]. However, another study found few
differences between LDSCs isolated from young and old ACL
tissue, with a comparable phenotype and multipotency [26].
Stem cells derived from ruptured human ACL remnants
and healthy tissue show a similar morphology, clonogenic
capacity, stem cell marker expression profile, and multipo-
tency [20, 21]. Further analysis into the effects of ACL rupture
on LDSC phenotype showed a decline in LDSC function with
increasing time since rupture. LDSCs isolated from acutely
injured ACL demonstrated very similar characteristics to
those from healthy tissue, whereas cells isolated from chronic
injuries showed a reduction in clonogenic potential and
multipotency [38].
3.6. An Alternative Source of LDSCs. The cells isolated
in the aforementioned studies have all been negative for
haematopoietic and endothelial markers; however, one group
has identified a cell population within the ACL which is
positive for CD34 [37, 39], suggesting an alternative vascular
source for stem cells located within the ACL. This group
identified two populations of cells within ACL tissue: CD34+
and CD34−. CD34+ cells lost expression of CD34 with
passaging (whereas expression ofMSCmarkers such asCD44
and STRO1 increased), and this population of cells retained
the ability to form endothelial cells to a greater extent than
that of CD34− populations [37, 39]. It is likely that LDSC
populations are heterogeneous and are in fact a mixed pop-
ulation of cells. The studies mentioned in previous sections
may be analysing gene expression at too late a passage to
detectCD34 expression.Alternatively, the presence ofCD34+
cells within ACL may be a consequence of ACL rupture, as
both studies analysed injured tissue. Further investigation in
to the phenotype of these differing cell populations and their
capacity for ligament repair is warranted.
4. The Use of MSCs in Ligament Repair
There is a wealth of literature on the use of MSCs for the
repair of ligament, particularly ACL. Studies have usedMSCs
to repair damaged ACL, as well as using them to enhance
healing of ACL tissue after reconstruction surgery.
A variety of approaches have been utilised to aid in
repairing of ACL with MSCs. One such technique involved
injection of MSCs alone into induced ACL tears in a rat
model. The addition of MSCs improved ligament tissue for-
mation and increased ultimate failure load when compared
with control animals [8]. Other studies have used biosyn-
thetic scaffolds alongside MSCs to improve ACL repair. The
addition of a collagen type I scaffold seeded with MSCs
to induced ACL injuries in a rabbit model resulted in
improved tissue regeneration with an organised collagen and
vascular structure [9]. Silk-based scaffolds have also shown
promising results, with MSCs expressing ligament-specific
extracellular matrix components and producing ligament-
type tissue when implanted with silk scaffolds into a porcine
injury model [40].
MSCs have been used to enhance healing of tendon
grafts used in ACL reconstruction surgeries. Rabbit Achilles
tendons were irradiated and seeded with MSCs before
implantation into the ACL site. MSCs increased cellular
infiltration and collagen deposition in the repairing tissue
[41]. In addition, seeding MSCs on to rabbit hamstring
tendon grafts promoted fibrocartilage formation and tendon-
bone healing [42].
It is clear that MSCs provide a promising therapeutic
option for the treatment of ACL injuries; however, a number
of studies have indicated the inferiority ofMSCs for treatment
of tendon/ligament injuries when compared with native cells
isolated from the tissue of interest. Stem cells derived from
ligament demonstrate increased clonogenicity and ligament
ECM gene expression when compared with bone marrow-
derived MSCs (BMMSCs) [14, 25], and collagen scaffolds
seeded with tendon cells and implanted into injured tendon
showed improved mechanical properties compared with
BMMSCs [43]. In addition, stem cells isolated from tendon
demonstrate increased clonogenicity, proliferation, multipo-
tency, and stem cell and tenogenic marker expression when
compared with BMMSCs [44]. These studies suggest that
cells derived from tendon and ligament themselves would
ameliorate therapeutic outcomes for tendon and ligament
injury when compared with BMMSCs.
5. The Use of LDSCs in Ligament Repair
Recent studies have investigated the use of PDLSCs in
tissue engineering approaches in dentistry for the repair of
periodontal cementum/bone and ligament with successful
outcomes [12, 13, 45]; however, little research has been
conducted in to the use of LDSCs for other forms of ligament
repair.
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Figure 3: The potential factors comprising the ligament stem cell niche.
One study has used rabbit stem cells derived from the
MCL in order to repair a MCL injury. When introduced
to the injury site, MCL stem cells (MCLSCs) alone induced
repair and remodelling with expression of collagen type I and
the formation of aligned collagen fibres, as well as increased
vascularisation. Functional recovery was also assessed with
the use of MCLSCs aiding ligament formation better able
to withstand mechanical strain and failure loads. However
the addition of CD34+ cells derived from human umbilical
cord blood in combination with MCLSCs produced an even
greater effect than MCLSCs or CD34+ cells alone. Collagen
expression was increased, the fibre alignment scores were
higher, vascularisation was increased, and also increased
failure loads were tolerated [18]. This study highlights the
potential use of LDSCs for repair of ligament injuries outside
the field of dentistry. In addition, this study demonstrates that
although LDSCs can promote repair of ligament injury, the
addition of other cell types allows this healing effect to be
increased.
As previously discussed, LDSCs positive for CD34 have
also been isolated from ACL tissue and one study has used
these cells to investigate the effects of angiogenesis on ACL
repair strategies [46]. CD34+ ACLDSCs were transfected
with vascular endothelial growth factor (VEGF) and grown
in to cell sheets which were wrapped around tendon grafts.
These grafts were then implanted into rat joints, in place
of previously excised ACLs. The grafts in combination with
the cell sheets exhibited increased tensile strength and load
to failure when compared with tendon grafts alone. In
addition, tendon-bone healing was increased with the use
of LDSC sheets, with improved collagen fibre alignment and
increased collagen production. The main focus of the study
was to assess vascularisation of healing tissue, andwith LDSC
sheets angiogenesis was significantly increased compared
with tendon graft only controls. A VEGF antagonist was also
used to show the expected decrease in angiogenesis in the
absence of VEGF, which also revealed a decrease in tendon-
bone healing [46]. This study demonstrates the potential of
vascular-derived LDSCs in treatment strategies for ligament
repair as well as the importance of angiogenesis during
ligament healing.
6. The LDSC Niche
There is currently very little known about the LDSC niche
and, as with the majority of research focussing on LDSCs,
studies investigating the niche have mainly focussed on
periodontal ligament; however, there are a few studies which
have investigated and identified key components of the niche
for nondental LDSCs (Figure 3).
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6.1. Extracellular Matrix. The composition and structure of
the ECM have been found to have significant effects on
various stem cells including PDLSCs [12, 47] and TDSCs
[48, 49], and so it is likely that the ECM has an impact on
LDSC viability and function, although to date no studies have
investigated this.
6.2. Oxygen Tension. Oxygen tension has been shown to
increase metabolism and collagen expression of stem cells
isolated from ACL [23].
6.3. Biological Mediators. The presence and quantity of cer-
tain biological mediators also have an impact on LDSC
properties. For ACLDSCs, certain media formulations and
the presence of specific growth factors, for example, FGF
and TGF-𝛽1, influence various stem cell properties, including
proliferation and multipotency [24]. ACLDSCs transfected
with BMP-12 and BMP-13 demonstrate increased ECM
production [50], indicating the likely importance of these
mediators in tissue homeostasis.
6.4. Cell Interactions. Although no studies have investigated
the link between ligamentocytes and LDSCs in the stem cell
niche, research has identified other cell types which play a
key role in regulating LDSC function. For example, BMMSCs
differentiate into ACL cells when cocultured with ACL
fibroblasts [51]; therefore, the influence of ACL fibroblasts
on MSC differentiation may indicate their role in LDSC
differentiation.
6.5. Vasculature and Innervation. As with tendon, ligament
is poorly vascularised and innervated [4]; however, it is likely
that these two factors still play a role within the stem cell
niche. As previously discussed, one group have found CD34+
stem cells within human ACL tissue which possess all the
properties found in other LDSCs [39]. This suggests that
LDSCs may be derived from pericytes and the vasculature.
If this is indeed the case, then the vasculature as a source of
LDSCs is a vital part of the ligament stem cell niche. However,
other studies have shown null expression of haematopoietic
and endothelial markers in LDSCs [15, 21], suggesting the
presence of two sources of LDSCs.
7. Therapeutic Manipulation of
the Stem Cell Niche
Manipulation of stem cells in vivo via modulation of the stem
cell niche holds therapeutic potential for the treatment of
a number of conditions. Although stem cell therapies show
promising results and successful outcomes, there are a num-
ber of issues associated with cell transplantation therapies.
The use of autologous stem cells, and the associated isolation,
culture and implantation of cells can be expensive and a long
process involving invasive and painful techniques in order to
extract cells from the patient. Allogeneic stem cells can be
used to avoid some of these issues; however, immunosuppres-
sion may then be required which can result in problematic
long-term side effects. In addition, whether autologous or
allogeneic cells are used, the survival of these cells when
introduced into wounds or diseased tissue is low [52].
A possible alternative to stem cell transplantation ther-
apies is modulation of stem cells in vivo which can be
achieved via manipulation of the stem cell niche. This can
promote survival, proliferation, and differentiation of stem
cells. Costly and time-consuming laboratory processes can
be avoided, as well as invasive surgical techniques and the
requirement for immunosuppressants. Several clinical trials
are currently underway or have been recently completed
which are investigating the safety and efficacy of stem cell
modulation therapies. For example, the administration of
a thrombopoietin mimetic to patients with severe aplastic
anaemia has been shown to increase haematopoietic stem
cell numbers as well as differentiation of these cells [53,
54], demonstrating the benefit of targeting secreted factors
for stem cell modulation. Granulocyte/macrophage colony
stimulating factor (GM-CSF) has been shown to regulate
survival, proliferation, and differentiation of a number of
stem cell types andwhen injected into chronic skin ulcers can
cause modulation of the stem cell niche by increasing vascu-
larisation [55]. This work indicates the potential advantages
of targeting other cell types within the stem cell niche.
Therefore, it is possible that modulation of the ligament
stem cell niche could also influence the behaviour of ligament
stem cells in vivo and provide potential therapeutic benefits.
As the quantity of research surrounding ligament stem cells
increases, it may be possible to identify specific factors within
their stem cell niche which can be targeted to produce a
desired change in phenotype and/or function. This approach
could provide a new therapeutic strategy to treat ligament
injury and degeneration.
8. Conclusion
Although the number of studies investigating LDSCs of
nondental origin is increasing, particularly in recent years,
there is still very little information on many aspects of these
cells. Further investigation is required into characterisation,
function, and therapeutic potential of LDSCs of nondental
origin. Investigation into cellular marker expression and the
identification of LDSC-specific markers would be beneficial
for future research in this area, as well as aiding clinical
implementation. Very little research has investigated the
survival and function of LDSCs in vivo or utilised these cells
for tissue engineering strategies in animal models; therefore,
the true therapeutic potential of these cells is as yet unknown
and is a promising area for future research.
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